Abstract:
Objective: To assess the e ects of trimetazidine (TMZ) added to conventional drug therapy on cardiac autonomic nervous CANS in patients with coronary heart disease (CHD) after the percutaneous coronary intervention (PCI). Study Design: Descriptive study. Place and Duration of Study: Department of Cardiology, The Second Hospital of Hebei Medical University, Hebei, China, from May 2018 to September 2019. Methodology: The study included 50 patients with CHD after a successful PCI who received trimetazidine plus conventional therapy were included as cases (exposed group), and 50 matched patients were identi ed as controls (non-exposed group). Heart rate (HR) and heart rate variability (HRV) parameters including sympathetic activity (SDNN, LF), parasympathetic activity (RMSSD, pNN50, SDSD, HF), and sympathovagal balance (LF/HF ratio) were used to evaluate CANS function. Results: There were no statistical di erences in the HR and HRV parameters before and after PCI (p>0.05). In the non-exposed group, conventional therapy signi cantly improved the HRV parameters (all p0.05). In the exposed group, all HRV parameters except HR were improved after 4 weeks of treatment. After 4 weeks of treatment, the exposed group had higher parasympathetic-nerve activity, lower sympathetic-nerve activity, and LF/HF ratio compared to the non-exposed group (all p<0.05). Conclusions: The application of TMZ based on conventional therapy e ectively improved the CANS in CHD patients who underwent PCI.
Page(s):
559-564
DOI:
DOI not available
Published:
Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 5, Year: 2022
Keywords:
Percutaneous Coronary Intervention
,
Coronary heart disease
,
Heart
,
Trimetazidine
,
Cardiac autonomic nervous system